Artelo biosciences reports first quarter 2024 financial results and provides business update

Solana beach, calif., may 13, 2024 (globe newswire) --  artelo biosciences, inc.  (nasdaq: artl) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended march 31, 2024 and provided a business update.
ARTL Ratings Summary
ARTL Quant Ranking